Sugi Predict

Sugi Predict / Targets / CDC25C

CDC25C

M-phase inducer phosphatase 3 · P30307 · CDC25C on Sugi Atlas →

11,750 patent compounds predicted against CDC25C, 7,613 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL82554 SCHEMBL82554 0.69 6/20
SCHEMBL733215 SCHEMBL733215 0.59 6/20
SCHEMBL1916880 SCHEMBL1916880 1.00 5/20
SCHEMBL1917474 SCHEMBL1917474 1.00 5/20
SCHEMBL1917644 SCHEMBL1917644 0.80 5/20
SCHEMBL64776 SCHEMBL64776 0.58 5/20
SCHEMBL893374 SCHEMBL893374 0.57 5/20
SCHEMBL170030 SCHEMBL170030 0.42 5/20
SCHEMBL670391 SCHEMBL670391 0.42 5/20
SCHEMBL187581 SCHEMBL187581 0.39 5/20
SCHEMBL45540 SCHEMBL45540 0.34 5/20
SCHEMBL359187 SCHEMBL359187 0.33 5/20
SCHEMBL360696 SCHEMBL360696 0.33 5/20
SCHEMBL1917318 SCHEMBL1917318 1.00 4/20
SCHEMBL1917276 SCHEMBL1917276 0.78 4/20
SCHEMBL260558 SCHEMBL260558 0.71 4/20
SCHEMBL1033982 SCHEMBL1033982 0.38 4/20
SCHEMBL1394741 SCHEMBL1394741 0.62 3/20
SCHEMBL263566 SCHEMBL263566 0.60 3/20
SCHEMBL571861 SCHEMBL571861 0.57 3/20

Clinical trials — most relevant to CDC25C by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
Effect of Silymarin in Metastatic Colorectal Cancer Patients PHASE3UNKNOWN
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer PHASE2/PHASE3NOT_YET_RECRUITING
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression PHASE3RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC PHASE2COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma PHASE2COMPLETED
Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma PHASE1/PHASE2COMPLETED
A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck Cancer PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL) PHASE2COMPLETED
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) PHASE1/PHASE2RECRUITING
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors PHASE2RECRUITING
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas PHASE1COMPLETED
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel PHASE1COMPLETED
Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors PHASE1COMPLETED
Study of ABT-751 in Patients With Refractory Hematologic Malignancies PHASE1COMPLETED
Study of FCN-437c in Patients With Advanced Solid Tumors PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-segment Elevation Myocardial Infarction: EXAMINATION Study nanCOMPLETED
Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS) nanUNKNOWN
Immunophenotyping and Xist Gene in AML nanUNKNOWN
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies nanENROLLING_BY_INVITATION
Evaluation of the Clinical Outcome of Cyclosporine Short Infusion Versus Continuous Infusion Post Allogenic Stem Cell Transplantation nanCOMPLETED
Diagnostic and Prognostic Value of PTEN Expression in Functional and Pathological Endometrial Biopsies nanCOMPLETED
The Beneficial Effects of Pomegranate on Hearing of Patients Without Hemodialysis nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CDC25C binder may also engage these)

ProteinNameSimilarity
Q29029 — 1.000 Q29029 →
P48966 — 1.000 P48966 →
CDC25A M-phase inducer phosphatase 1 1.000 landscape →
P30310 — 1.000 P30310 →
A5D7P0 — 1.000 A5D7P0 →
P48968 — 0.999 P48968 →
A7MBD1 — 0.999 A7MBD1 →
P48964 — 0.997 P48964 →
P48967 — 0.997 P48967 →
P30309 — 0.996 P30309 →
P30311 — 0.996 P30311 →
P30308 — 0.996 P30308 →
CDC25B M-phase inducer phosphatase 2 0.995 landscape →
P48965 — 0.991 P48965 →
P30306 — 0.988 P30306 →
Q9JIC3 — 0.987 Q9JIC3 →
A4Q9E8 — 0.984 A4Q9E8 →
Q90Z80 — 0.983 Q90Z80 →
Q66JT0 — 0.983 Q66JT0 →
P12525 — 0.983 P12525 →
Q9Z0R0 — 0.983 Q9Z0R0 →
Q0IIM1 — 0.983 Q0IIM1 →
Q6IVY4 — 0.982 Q6IVY4 →
Q5SW75 — 0.982 Q5SW75 →
E1BE02 — 0.982 E1BE02 →
Q6P1H6 — 0.982 Q6P1H6 →
Q8BLR5 — 0.982 Q8BLR5 →
E1BTE1 — 0.982 E1BTE1 →
Q9JHS1 — 0.982 Q9JHS1 →
Q60795 — 0.981 Q60795 →